When was Acepodia founded?

Acepodia was founded in 2017 and raised its 1st funding round 4 years after it was founded.

Where is Acepodia located?

Acepodia is headquartered in Alameda, United States.

How many employees does Acepodia have?

As of Aug 31, 2026, the latest employee count at Acepodia is 61.

Is Acepodia a funded company?

Acepodia is a funded company, having raised a total of $256M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Mar 16, 2021.

When was the latest funding round of Acepodia?

Acepodia's latest funding was a $***** Series D round on Jun 06, 2023, with participation from 1 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $4.18B in funding in 2026 to date.

Where does Acepodia rank among its competitors?

Acepodia ranks 186th amongst 3381 active competitors, of which 1136 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Acepodia?

Acepodia's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Acepodia - 2026 Company Profile, Team, Funding & Competitors

Acepodia is a public company based in Alameda (United States), founded in 2017 by Sonny Hsiao and Patrick Y Yang. It operates as a Developer of cancer immunotherapy to treat ovarian and breast cancer. Acepodia has raised $256M in funding from investors like CDIB Capital, DEFTA Partners and Ridgeback Capital Management. The company has 3381 active competitors, including 1136 funded and 785 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Acepodia is developing cancer immunotherapy using antibody cell conjugation technology. The company's proprietary immune cells are developed by combining novel and well-established targeting mechanisms using Antibody-Cell Conjugation (ACC) and Chimeric Antigen Receptor (CAR) technology. It forms the antigen-antibody complex and helps to eradicate cancer cells. Its pipeline candidate includes ACE1702 is under the preclinical stage that will use to treat ovarian and breast cancer. Its other products include ACE1708 and AAT1805 to treat lymphoma.

Website: www.acepodia.com/
Social
Email ID: *****@acepodiabio.com
Phone Number: +886 **********

Key Metrics

Founded Year

2017

Location

Alameda, United States

Stage

Public

Total Funding

$256M in 3 rounds

Latest Funding Round

Series D, Jun 06, 2023, $*****

Investors

CDIB Capital & 11 more

Ranked

186^th among 3381 active competitors

Employee Count

61 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3051 more

Exit Details

Public

View Acepodia's full profile

Acepodia got listed on Aug 08, 2023.

Click here to take a look at Acepodia's IPO in detail

Acepodia has raised a total funding of $256M over 3 rounds. Its first funding round was on Mar 16, 2021. Its latest funding round was a Series D round on Jun 06, 2023 for $*****. 1 investor participated in its latest round. Acepodia has 9 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of Acepodia:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 06, 2023	6815351	Series D	8543217	6123876	6283637	3101483
Dec 02, 2021	9538289	Series C	8369209	4977952	6001283	1467279
Mar 16, 2021	7224918	Series B	6598496	2046333	Ridgeback Capital Management & 5 more	Samuel Chen & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Acepodia's funding rounds and investors

The founders of Acepodia are Sonny Hsiao and Patrick Y Yang.

Here are the details of Acepodia's key team members:

Sonny Hsiao: Founder of Acepodia.
Patrick Y Yang: Founder of Acepodia.

View details of Acepodia's Founder profiles and Board Members

Acepodia's employee count trend

Acepodia has 61 employees as of Aug 26. Here is Acepodia's employee count trend over the years:

Uncover Acepodia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Acepodia include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Acepodia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
186th	Acepodia 2017, Alameda (United States), Public	Developer of cancer immunotherapy to treat ovarian and breast cancer	$256M	Ridgeback Capital Management, M Venture Investment ... & 10 others	59/100